Literatur
[1] Bork K, Aygören-Pürsün E, Bas M et al. Leitlinie: Hereditäres Angioödem durch C1-Inhibitor-Mangel. Allergo J Int 2019, 28:16-29, AWMF-Register-Nr. 061/029
[2] Maurer M, Magerl M, Betschel S et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy 2022, 77(7):1961-1990
[3] Wilkerson RG, Moellman JJ. Hereditary Angioedema. Emerg Med Clin North Am 2022, 40(1):99-118
[4] Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med 2020, 382(12):1136-1148
[5] Fachinformationen, Takeda, abgerufen am 19. August 2023, Berinert®: www.fachinfo.de/api/public/fachinfo/pdf/006837, Cinryze®: www.fachinfo.de/api/public/fachinfo/pdf/013115, Ruconest® : www.fachinfo.de/api/public/fachinfo/pdf/012937
[6] Craig TJ, Reshef A, Li HH et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023, 401(10382):1079-1090
[7] CLS Behrig. CLS-Phase III-Studie zu Garadacimab. Lancet-Magazin, abgerufen am 19. August 2023, www.cslbehring.de/news/2023/pm-garadacimab-lancet
[8] ClinicalTrials.gov. Long-term safety and efficacy of CSL312 (Garadacimab) in the prophylactic treatment of hereditary angioedema attacks. NCT04739059, https://classic.clinicaltrials.gov/ct2/show/NCT04739059
[9] Fachinformation zu Orladeyo®. Takeda, abgerufen am 19. August 2023, www.fachinfo.de/api/public/fachinfo/pdf/023436
[10] Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010, 6(1):29-39
[11] Murphy K, Weaver C. Janeway Immunologie. Springer 2018, 9.Auflage
[12] Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem 2009, 7(3):234-250
[13] Biglarnia AR, Huber-Lang M, Mohlin C et al. The multifaceted role of complement in kidney transplantation. Nat Rev Nephrol 2018, 14:767–781
[14] Qi R, Qin W. Role of complement system in kidney transplantation: Stepping from animal models to clinical application. Front Immunol 2022, 13:811696
[15] Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 2014, 6(5):533-551
[16] Fachinformation Firazyr®. Takeda, abgerufen am 19. August 2023, www.fachinfo.de/api/public/fachinfo/pdf/011316
[17] Fachinformation Takhzyro®. Takeda, abgerufen am 19.August 2023, www.fachinfo.de/api/public/fachinfo/pdf/023125
[18] Fachinformation Cyklokapron®. Takeda, abgerufen am 19.August 2023, www.fachinfo.de/api/public/fachinfo/pdf/007045
0 Kommentare
Das Kommentieren ist aktuell nicht möglich.